Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2010 - 2026)

Neurocrine Biosciences has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $144.4 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at $144.4 million, up 34.33% year-over-year; the trailing twelve-month figure through Jun 2026 was $705.5 million (up 102.56% YoY), and the FY2025 annual result was $478.6 million, up 40.23% from the prior year.
• Net Income towards Common Stockholders fell to $144.4 million in Q2 2026, from $197.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $209.5 million in Q3 2025 and troughed at -$76.6 million in Q1 2023.
• A 5-year average of $87.0 million and a median of $92.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2023, when Net Income towards Common Stockholders slumped 651.08%; it then soared 2405.06% in 2026.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $89.0 million in 2022, then jumped by 65.96% to $147.7 million in 2023, then plunged by 30.2% to $103.1 million in 2024, then surged by 49.08% to $153.7 million in 2025, then decreased by 6.05% to $144.4 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $144.4 million in Q2 2026, $197.9 million in Q1 2026, and $153.7 million in Q4 2025.